Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers. The FDA enlisted Aptar to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of […]
aptarpharma
Aptar Pharma launches metal-free nasal spray pump
Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity. Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) formulations. The company designed the pump specifically for recyclability. It represents Aptar’s first “highly recyclable” nasal spray pump, according to a […]
Aptar acquires Orbital dry powder inhaler license
Aptar Pharma announced today that it acquired the worldwide writes to Pharmaxis’ proprietary Orbital inhaler. Pharmaxis designed its Orbital technology to deliver high-payload dry powder to the lungs, helping to meet the need to deliver high doses of drugs such as antibiotics. According to a news release, the Orbital inhaler allows payloads of up to […]
FDA approves first nasally administered pharmaceutical treatment for dry eye
AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye. Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s […]
Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate
Seelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device. The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device to deliver Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD). Under the agreement, Seelos garners certain rights to […]
Aptar wins FDA clearance for ready-to-use seizure treatment device
AptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy. The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs. “This approval and successful market launch further demonstrate the broad […]
Aptar Pharma’s two-dose nasal spray device to deliver epinephrine
Aptar Pharma has entered an agreement for Bryn Pharma to use Aptar’s Bidose (BDS) nasal device to deliver Bryn’s epinephrine nasal spray (BRYN-NDS1C). Crystal Lake, Ill.-based Aptar’s Bidose tech enables two-shot nasal drug delivery and will replace the need to carry two epinephrine auto-injectors, according to the companies. Last March, Aptar won FDA approval to […]
Eli Lilly, Aptar win FDA approval for nasal glucagon powder
Eli Lilly (NYSE:LLY) and AptarGroup (NYSE:ATR) today won FDA approval for the first injection-free glucagon for treating severe low blood sugar in diabetes patients. The federal safety watchdog’s approval, of Lilly’s Baqsimi nasal powder and the delivery device developed by Aptar for treating severe hypoglycemia, was based on two studies comparing a single dose of Baqsimi […]
Aptar Pharma touts FDA approval of nasal spray device
Aptar Pharma said this week that its Bidose nasal spray device won FDA approval for use with a breakthrough depression therapy. The Crystal Lake, Ill.-based company’s Bidose tech enables two-shot nasal drug delivery. Aptar touted its manufacturing facility in Congers, NY, which supports the manufacture of nasal and injectable drug delivery systems. “We are pleased […]
Propeller Health touts investment from McKesson Ventures
Building on a $20 million funding round announced last month, Propeller Health said today that it landed an investment of an undisclosed amount from McKesson Ventures. The company is looking to expand its digital therapeutics business beyond devices that manage the treatment of chronic respiratory diseases. Propeller noted that it’s interested in exploring opportunities in […]
